We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
How to use an ethnographic study to evaluate your digital health product.
Guidance, key documents, and CMA decisions on the review of PPU arrangements under the Private Healthcare Market Investigation Order 2014.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer. Information on the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or...
How to use a cost effectiveness analysis to evaluate your digital health product.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
How to use a crossover randomised controlled trial to evaluate your digital health product.
An annual publication providing statistics on restricted patients in England and Wales
A retrospective cohort study involving the review of laboratory and TB registers
Reviews the findings from the 2012/13 Patient Level Information and Costing Systems (PLICS) pilot data collection for admitted patient care.
How to use an interrupted time series to evaluate your digital health product.
Information about when you need to submit substantial amendments to a clinical trial including changes to the trial sponsor or legal representative, Investigational medicinal product certification and importation.
Details of the Yellow Card scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
The following guidance has been jointly developed by the Heath Research Authority (HRA) and MHRA, in consultation with the Information Commissioners Office (ICO), on behalf of the UK.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).